Eupraxia Pharmaceuticals Inc.

TSX:EPRX.TO

Biotechnology

Healthcare
$8.86 +2.49%

+$0.22 today

Market cap
$595.76M
Beta
1.48
P/E (TTM)
-8.6
EPS (TTM)
-$0.74
52W Low $5.82High $12.86

Volume 0.16M

Average 0.05M

EPRX.TO Total Debt

Short-term and long-term borrowings combined.

Eupraxia Pharmaceuticals Inc.TSX: EPRX.TO

Total Debt · Q1 FY2026 · quarter ended Mar 2026

Total debt rises 3666.4% from a year ago

Total debt stood at $2.01M at the end of Q1 FY2026, up 3666.4% from a year earlier and up 1203.4% from the prior quarter. Over 3 fiscal years it compounded at -75.6% a year.

Context

  • Total debt amounted to 1.4% of total assets at the end of Q1 FY2026, up 1.2 pp from a year earlier.
  • Total debt increased in 1 of the last 3 fiscal years.

What to watch

Whether total debt keeps rising in the next quarterly balance sheet after a +3666.4% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.01M+1203.4% QoQ
Last fiscal yearDec 2025
$154.08K+114.4% YoY
Year agoMar 2025
$53.32K+3666.4% since
Total Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+3666.4%——
1 year+114.4%——
3-year CAGR-75.6%——
5-year CAGR——
10-year CAGR——

Total Debt history

Mixed currencies · from the balance sheet

Latest · FY2025
154.08K USD
Year-over-year change
+114.4%

Total Debt vs competitors

How EPRX.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so total debt is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +3666.4% is the highest of 7, against a peer median of -16.8%.
  • Total debt amounts to 1.4% of total assets for EPRX.TO, versus a peer median of 10.2%.
EPRX.TO Competitors
Total Debt for EPRX.TO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
WEED.TOCanopy Growth CorporationMar 2026CA$278.71M CAD-20.0%-41.8%24.9%
TSND.TOTerrAscend Corp.Mar 2026$254.03M USD+3.3%+1.1%46.2%
DR.TOMedical Facilities CorporationMar 2026$57.24M USD-19.5%-25.7%20.6%
OGI.TOOrganiGram Holdings Inc.Mar 2026CA$8.2M CAD-14.0%—1.6%
PRN.TOProfound Medical Corp.Mar 2026$7.47M USD+52.9%-17.3%10.2%
EPRX.TOEupraxia Pharmaceuticals Inc.Mar 2026$2.01M USD+3666.4%-75.6%1.4%
HBP.TOHelix BioPharma Corp.Apr 2026CA$359K CAD—-48.6%1.7%
FRX.TOFennec Pharmaceuticals Inc.Mar 2026$0 USD-100.0%—0.0%
Peer median (excluding EPRX.TO) —-16.8%-25.7%10.2%

Competitors are the stored peer set for EPRX.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

Mixed currencies
Metric
FY2021
Dec 2021 · CAD
FY2022
Dec 2022 · CAD
FY2023
Dec 2023 · USD
FY2024
Dec 2024 · USD
FY2025
Dec 2025 · USD
Cash & Equivalents20.89M24.74M19.2M33.1M80.42M
Short-term Investments9.01M0000
Net Receivables337.03K121.51K190.61K228.87K673K
Inventory00000
Other Current Assets151.14K10900(7.02K)
Total Current Assets30.6M25.18M19.8M34.44M84.94M
Property, Plant & Equipment (Net)589.07K695.48K452.97K424.92K985.33K
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets31.37K3.37K6.85K80.76K64.22K
Total Non-current Assets620.44K698.85K459.82K505.68K1.05M
Total Assets31.22M25.88M20.12M34.94M85.99M
Account Payables00000
Short-term Debt74.44K107.53K10.37M71.82K78.31K
Tax Payables0036.16K00
Deferred Revenue003.06K00
Other Current Liabilities1.4M1.55M2.73M(1.5M)1.43M
Total Current Liabilities2.27M4.14M19.23M4.46M5.62M
Long-term Debt9.26M10.3M000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities29.71K0000
Total Non-current Liabilities9.4M10.37M0075.77K
Total Liabilities11.67M14.51M19.23M4.46M5.69M
Common Stock80.71M92.34M69.96M116.36M195.05M
Retained Earnings(74.19M)(97.45M)(79.43M)(131M)(169.27M)
Accumulated OCI00(2.7M)(5.98M)(2.04M)
Other Stockholders Equity00662.23K1.82M0
Minority Interest(833.84K)(1.49M)(1.32M)(1.57M)(1.59M)
Total Equity19.55M11.36M892.33K31.84M80.3M
Total Debt9.49M10.55M10.45M71.86K154.08K
Net Debt(11.4M)(14.19M)(8.83M)(33.03M)(80.26M)

Eupraxia Pharmaceuticals Inc.

TSX:EPRX.TO

Intrinsic Alpha fair value

Locked

Current Price

$8.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.